Zydus Cadila, an Ahmedabad-based innovative, global pharmaceutical company, announced that the company has presented new scientific and clinical data on saroglitazar at the 75th Annual Scientific Sessions of the American Diabetes Association (ADA) in Boston, Massachusetts, USA.  

Speaking on the development, Pankaj R Patel, chairman and managing director, Zydus Cadila said, “These new robust scientific data on the safety and efficacy of Lipaglyn (saroglitazar) presented at the 75th Annual Scientific Sessions of the American Diabetes Association (ADA) reflect our continued commitment to millions of patients living with diabetes, dyslipidemia, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).”

Lipaglyn (saroglitazar) was launched in September 2013 in India, for treating hypertriglyceridemia and diabetic dyslipidemia in patients with type 2 diabetes not controlled by statins. Since then, more than 80,000 patients are availing this drug with a prescriber base over 3500 diabetologists, cardiologists and physicians. Lipaglyn helps in a reduction of triglycerides and LDL (bad) cholesterol, and an increase in HDL (good) cholesterol and has also shown a reduction in Fasting Plasma Glucose and glycosylated haemoglobin (HbA1c), thereby confirming its beneficial effects on both lipid and glycemic control in diabetic patients. Lipaglyn is a prescription medicine, and can be taken only under the advice and guidance of a registered medical practitioner.